Correlation Between The Screening, Assessment Of Nutritional Status And Skeletal Metastasis In Non-Small Cell Lung Cancer (NSCLC)- A Retrospective Study
DOI:
https://doi.org/10.63682/jns.v14i4.9019Keywords:
NSCLC,, SGA, Screening, metastasis, anxietyAbstract
Background: Lung carcinoma has developed over the past century from a rare and obscure disease to the most frequent cancer worldwide and the leading cause of cancer-related death. A collection of histological subtypes known as non-small cell lung cancer (NSCLC) affects about 85% of patients.
Aim: This study aims to determine the screening, correlating between the assessment of nutritional status and skeletal metastasis in non-small cell lung cancer, the prevalence, and the risk factors involved.
Methods: It was conducted at the Department of Medical Oncology, JSS Hospital, Agrahara, Mysuru from April to 30th June 2024 for 3 months involving 100 patients diagnosed with NSCLC.
Result: The prevalence rate of NSCLC in this study is higher in males than females in the age group 66-75 with more stages 3 and 4. Most patients obtained chemotherapy with anxiety, fatigue, breathlessness, and other symptoms. Diabetes and hypertension were seen as the most risk factors. BMI analysis showed a normal nutritional status in about 45-50% of patients, but screening and assessment showed a high risk of malnutrition and malnourishment. Skeletal metastasis is seen more in males than females.
Conclusion: From this study we understand that smoking habits play an important role in the progression of the disease as of male population is more addicted to it which impacts the prevalence rate in both males and females. Also, BMI alone can`t be used for the malnutrition analysis or nutritional status, screening and assessment test are must in assessing the patients. Decrease in nutritional status impacts higher in skeletal metastasis as the body loss its essential elements which impacts on the quality of life.
Downloads
Metrics
References
De Groot PM, Wu CC, Carter BW, Munden RF. The epidemiology of lung cancer. Translational lung cancer research. 2018 Jun;7(3):220.
Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature. 2018 Jan 25;553(7689):446-54.
Schabath MB, Cote ML. Cancer progress and priorities: lung cancer. Cancer epidemiology, biomarkers & prevention. 2019 Oct 1;28(10):1563-79.
Relli V, Trerotola M, Guerra E, Alberti S. Abandoning the notion of non-small cell lung cancer. Trends in molecular medicine. 2019 Jul 1;25(7):585-94.
World Health Organization. Cancer Fact Sheet. https://www.who.int/news-room/fact-sheets/detail/cancer (2018).
Wang M, Herbst RS, Boshoff C. Toward personalized treatment approaches for non-small-cell lung cancer. Nature medicine. 2021 Aug;27(8):1345-56.
Yang P, Allen MS, Aubry MC, et al. Clinical features of 5,628 primary lung cancer patients: experience at Mayo Clinic from 1997 to 2003. Chest. 2005;128(1):452-462.
Zhang H, Cai B. The impact of tobacco on lung health in China. Respirology. 2003;8(1):17-21.
Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. InMayo clinic proceedings 2008 May 1 (Vol. 83, No. 5, pp. 584-594). Elsevier.
Cho J, Choi SM, Lee J, Lee CH, Lee SM, Kim DW, Yim JJ, Kim YT, Yoo CG, Kim YW, Han SK. Proportion and clinical features of never‐smokers with non‐small cell lung cancer. Cancer Communications. 2017 Dec;36(1):1-7.
Horn L., Spigel D.R., et al. Nivolumab Versus Docetaxel in Previously Treated Patients with Advanced Non–Small-Cell Lung Cancer: Two-Year Outcomes from Two Randomized, Open-Label, Phase III Trials (Check Mate 017 and Check Mate 057) J. Clin. Oncol. 2017; 35:3924–3933.
Emel J.S., Greer J.A., Goldberg S., Vogel P.D., Sullivan M., Pirl W.F., Lynch T.J., Christiani D.C., Smith M.R. A Structured Exercise Program for Patients with Advanced Non-Small Cell Lung Cancer. J. Thorac. Oncol. 2010; 4:595–601.
Lutz S., Norrell R., Bertucio C., Kachnic L., Johnson C., Arthur D., Schwarz M., Palardy G. Symptom Frequency and Severity in Patients with Metastatic or Locally Recurrent Lung Cancer: A Prospective Study Using the Lung Cancer Symptom Scale in a Community Hospital. J. Palliat. Med. 2001; 4:157–165.
Lemjabbar-Alaoui H, Hassan OU, Yang YW, Buchanan P. Lung cancer: Biology and treatment options. Biochimica et Biophysica Acta (BBA)-Reviews on Cancer. 2015 Dec 1;1856(2):189-210.
Tsim S, O’Dowd CA, Milroy R, Davidson S. Staging of non-small cell lung cancer (NSCLC): a review. Respiratory medicine. 2010 Dec 1;104(12):1767-74.
Woodard GA, Jones KD, Jablons DM. Lung cancer staging and prognosis. Lung cancer: treatment and research. 2016:47-75.
Li D, Yuan X, Liu J, Li C, Li W. Prognostic value of the prognostic nutritional index in lung cancer: a meta-analysis. Journal of thoracic disease. 2018 Sep;10(9):5298.
Takayama K, Atagi S, Imamura F, Tanaka H, Minato K, Harada T, Katakami N, Yokoyama T, Yoshimori K, Takiguchi Y, Hataji O. Quality of life and survival survey of cancer cachexia in advanced non-small cell lung cancer patients—Japan nutrition and QOL survey in patients with advanced non-small cell lung cancer study. Supportive Care in Cancer. 2016 Aug; 24:3473-80.
Frega S, Ferro A, Bonanno L, Guarneri V, Conte P, Pasello G. Sex-based heterogeneity in non-small cell lung cancer (NSCLC) and response to immune checkpoint inhibitors (ICIs): a narrative review. Precision Cancer Medicine. 2021 30;4.
Goyal G, Kommalapati A, Bartley AC, Gunderson TM, Adjei AA, Go RS. Association between hospital volume and mortality of patients with metastatic non-small cell lung cancer. Lung Cancer. 2018 Aug 1; 122:214-9.
Ahn BC, Pyo KH, Xin CF, Jung D, Shim HS, Lee CY, Park SY, Yoon HI, Hong MH, Cho BC, Kim HR. Comprehensive analysis of the characteristics and treatment outcomes of patients with non-small cell lung cancer treated with anti-PD-1 therapy in real-world practice. Journal of cancer research and clinical oncology. 2019 Jun 1; 145:1613-23.
Xing PY, Zhu YX, Wang L, Hui ZG, Liu SM, Ren JS, Zhang Y, Song Y, Liu CC, Huang YC, Liao XZ. What are the clinical symptoms and physical signs for non‐small cell lung cancer before a diagnosis is made? A nationwide multicenter 10‐year retrospective study in China. Cancer medicine. 2019 Jul;8(8):4055-69.
Cedzyńska M, Przepiórka IA. Cancer patients and smoking cessation. Nowotwory. Journal of Oncology. 2023;73(6):394-401.
Rios J, Gosain R, Goulart BH, Huang B, Oechsli MN, McDowell JK, Chen Q, Tucker T, Kloecker GH. Treatment and outcomes of non-small-cell lung cancer patients with high comorbidity. Cancer management and research. 2018 Jan 24:167-75.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
